ContraFect Corporation (CFRXQ)
OTCMKTS: CFRXQ · Delayed Price · USD
0.0100
-0.0020 (-16.67%)
Jul 19, 2024, 11:17 AM EDT - Market open
ContraFect Employees
ContraFect had 23 employees as of December 31, 2022. The number of employees decreased by 15 or -39.47% compared to the previous year.
Employees
23
Change (1Y)
-15
Growth (1Y)
-39.47%
Revenue / Employee
n/a
Profits / Employee
-$1,049,478
Market Cap
107.05K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
CFRXQ News
- 10 months ago - ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study - GlobeNewsWire
- 10 months ago - ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development - GlobeNewsWire
- 11 months ago - ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370 - GlobeNewsWire
- 11 months ago - ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 - GlobeNewsWire
- 1 year ago - ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million - GlobeNewsWire
- 1 year ago - ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens - GlobeNewsWire
- 1 year ago - ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023 - GlobeNewsWire